Skip to main content

Study Looks at Co-Use of CYP2D6-Metabolizing Opioids, Antidepressants in Seniors

Medically reviewed by Carmen Pope, BPharm. Last updated on July 23, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, July 22, 2024 -- For older nursing home (NH) residents, use of CYP2D6-metabolized opioids concomitantly with CYP2D6-inhibiting antidepressants is associated with worsening pain and increased risk of opioid-related adverse events (ORAEs), according to a study published online July 23 in the Annals of Internal Medicine.

Yu-Jung Jenny Wei, Ph.D., from the College of Pharmacy at The Ohio State University in Columbus, and colleagues examined the associations of concomitant use of CYP2D6-metabolized opioids and antidepressants with clinical outcomes and ORAEs in a retrospective cohort study using a target trial emulation framework. Data were included for 29,435 long-term residents aged 65 years and older receiving CYP2D6-metabolized opioids with a disease indication for antidepressant use who initiated CYP2D6-inhibiting versus CYP2D6-neutral antidepressants.

The researchers found that use of CYP2D6-metabolized opioids concomitantly with CYP2D6-inhibiting antidepressants was associated with increased adjusted rate ratio of worsening pain compared with CYP2D6-neutral antidepressants (1.13). In addition, CYP2D6-inhibiting antidepressants were associated with higher adjusted incidence rate ratios of pain-related hospitalization, pain-related emergency department visits, and opioid use disorder (1.37, 1.49, and 1.93, respectively); no differences were seen in physical function, depression, and opioid overdose.

"When co-use of CYP2D6-metabolizing opioids and antidepressants is clinically needed, selecting CYP2D6-neutral antidepressants, rather than CYP2D6-inhibiting antidepressants, may provide better or equal clinical and adverse outcomes," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted July 2024

Read this next

Buprenorphine for Opioid Use Disorder in Pregnancy Can Improve Outcomes

FRIDAY, May 2, 2025 -- For mothers with opioid use disorder (OUD), treatment with buprenorphine in pregnancy is associated with improved maternal and infant outcomes, according to...

Prior Military Sexual Trauma Linked to Late-Life Suicide Attempt

THURSDAY, May 1, 2025 -- Prior military sexual trauma (MST) is associated with late-life suicide attempt and death by suicide or overdose, according to a study published online...

Recent Years Saw Increase in Youth With Anxiety, Depression

MONDAY, April 28, 2025 -- From 2016 to 2022, there was an increase in the proportion of youth who experienced anxiety or depression, according to a research letter published...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.